Adtran wins two FTTH Innovation Awards for 50G PON and deep PON fiber monitoring
27.3.2025 16:00:00 CET | Business Wire | Press release
News summary: Adtran’s 50G PON fiber access solution and fiber monitoring platform recognized for their impact on advancing fiber broadband connectivity SDX 6405 OLT supports coexistence of GPON, XGS-PON and 50G PON on each port for seamless network scaling ALM with deep PON assurance delivers real-time, in-service fiber monitoring, enhancing network reliability and reducing opex costs
Adtran today announced that it has won two FTTH Innovation Awards at the FTTH Conference 2025, recognizing its SDX 6405 optical line terminal (OLT) and ALM fiber monitoring platform as standout technologies supporting next-generation fiber networks. Organized by the FTTH Council Europe, the annual awards highlight innovations that accelerate fiber broadband rollouts while improving scalability, operational efficiency and user experience. Adtran received awards in two categories: ‘Active infrastructure – central network’ and ‘Installation equipment, tools, test & measurement instruments.’
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326874284/en/
Adtran’s SDX 6405 OLT and ALM fiber monitoring platform received Innovation Awards at the FTTH Conference 2025.
“We’re honored to receive this recognition at the FTTH Conference. It’s a fantastic achievement for our team and a validation of the vision that’s guided our work: to help service providers build fiber networks that are open, scalable and ready for what comes next,” said Christoph Glingener, CTO of Adtran. “These wins reflect the dedication and expertise across our organization – from engineering to product to field support – and the close partnerships we’ve built with customers to solve real deployment challenges. Whether it’s enabling a future-proof transition to 50G PON or delivering affordable, real-time visibility into the access network, we’re focused on giving operators the tools to grow efficiently, improve reliability and stay ahead of demand.”
Adtran’s SDX 6405 won in the central network category for its 50G PON capabilities and disaggregated architecture. Part of the SDX 6000 Series, it supports GPON, XGS-PON and 50G PON on every port, enabling providers to deliver multigigabit services for residential, business and backhaul use cases – all over a single fiber. Its modular design eliminates the trade-off between near-term cost and long-term scalability. With the SDX 6405, providers can gradually add 50G OLTs to meet growing demand without disrupting existing subscribers or overhauling infrastructure. Built on an open, software-defined architecture, it integrates seamlessly into multivendor networks and supports automated service delivery through Adtran’s Mosaic Cloud Platform.
In the tools and measurement category, Adtran’s ALM was recognized for redefining how service providers monitor and manage fiber infrastructure. The compact, low-power device offers real-time, in-service visibility across the entire optical plant – enabling operators to detect and pinpoint issues before they affect customers. A key innovation is its deep PON assurance capability, which makes it possible to monitor fiber behind splitters without the need for demarcation reflectors. This is especially valuable for FTTH deployments, where scale and complexity can make fault detection and resolution a significant operational challenge. With support for fixed and mobile access networks, ALM empowers operators to increase service quality while lowering operational costs.
“These two awards recognize technologies that are solving critical challenges in access networks – from scaling bandwidth to ensuring new levels of service reliability,” commented Robert Conger, GM of software platforms and strategy at Adtran. “With 50G PON, we’re enabling a new generation of services that demand ultra-fast, highly reliable connectivity – whether that’s AI workloads, immersive experiences or industrial automation. At the same time, it delivers lower-speed services like 1G and 10G far more efficiently, helping operators simplify their access infrastructure and maximize return on investment. And with deep PON assurance, we’re giving operators the visibility they need to maintain those services at scale. It’s about building the foundation for sustainable, high-performance broadband that can evolve with demand.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326874284/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom